Alessandro Pocai Selected Research

Oxyntomodulin

6/2014	Action and therapeutic potential of oxyntomodulin.
8/2012	The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
4/2011	DPP-IV-resistant, long-acting oxyntomodulin derivatives.
10/2009	Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Pocai Research Topics

Disease

12	Obesity 06/2014 - 02/2004
10	Insulin Resistance 09/2009 - 09/2004
8	Weight Loss (Weight Reduction) 01/2019 - 10/2009
7	Body Weight (Weight, Body) 01/2019 - 06/2008
7	Type 2 Diabetes Mellitus (MODY) 01/2018 - 11/2002
5	Hyperglycemia 01/2012 - 11/2002
2	Chemical and Drug Induced Liver Injury 01/2019 - 01/2018
1	Heart Failure 04/2019
1	Hypertrophy 01/2018
1	Necrosis 01/2018
1	Drug-Related Side Effects and Adverse Reactions 01/2018
1	Dyslipidemias (Dyslipidemia) 07/2011
1	Hypoglycemia (Reactive Hypoglycemia) 04/2011
1	Nausea 04/2011
1	Glucose Intolerance 09/2009
1	Diabetes Complications 09/2008
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2007
1	Hyperphagia (Overeating) 11/2005
1	Diabetes Mellitus 01/2005

Drug/Important Bio-Agent (IBA)

18	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 11/2002
6	Glucagon Receptors (Glucagon Receptor)IBA 06/2014 - 10/2009
5	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019 - 10/2009
5	Peptides (Polypeptides)IBA 01/2014 - 10/2009
4	Glucagon (Glukagon)FDA Link 04/2019 - 04/2011
4	Insulin (Novolin)FDA Link 01/2019 - 06/2006
4	OxyntomodulinIBA 06/2014 - 10/2009
4	Glucagon-Like Peptide-1 ReceptorIBA 06/2014 - 10/2009
3	Hypoglycemic Agents (Hypoglycemics)IBA 11/2013 - 10/2009
3	LipidsIBA 08/2012 - 04/2006
3	Blood Glucose (Blood Sugar)IBA 01/2012 - 02/2004
2	Carboxylic AcidsIBA 01/2019 - 01/2018
2	Peptide Hormones (Polypeptide Hormones)IBA 06/2014 - 04/2011
2	neuromedin UIBA 01/2014 - 08/2012
2	Nonesterified Fatty Acids (NEFA)IBA 07/2008 - 02/2008
2	LeptinIBA 06/2008 - 11/2005
1	FluorineIBA 01/2019
1	TAK-875IBA 01/2018
1	Bile Acids and Salts (Bile Acids)IBA 01/2018
1	BilirubinIBA 01/2018
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2018
1	Human Serum Albumin FDA LinkGeneric 01/2014
1	Stearoyl-CoA DesaturaseIBA 07/2011
1	AcidsIBA 04/2011
1	Hormones (Hormone)IBA 04/2011
1	NF-kappa B (NF-kB)IBA 09/2008
1	Superoxides (Superoxide)IBA 09/2008
1	Ribosomal Protein S6 Kinases (S6 Kinase)IBA 08/2008
1	Phospholipid Transfer ProteinsIBA 07/2008
1	EndocannabinoidsIBA 06/2008
1	Dexamethasone (Maxidex)FDA LinkGeneric 02/2008
1	CannabinoidsIBA 01/2008
1	RimonabantIBA 01/2008
1	AdiponectinIBA 08/2007
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2007
1	PPAR alphaIBA 08/2007
1	Insulin ReceptorIBA 08/2007
1	Messenger RNA (mRNA)IBA 08/2007
1	VLDL LipoproteinsIBA 02/2007
1	Lactic Acid (Lactate)FDA LinkGeneric 02/2007
1	Leptin ReceptorsIBA 07/2006
1	stearoyl-coenzyme A (stearoyl-CoA)IBA 06/2006
1	OligodeoxyribonucleotidesIBA 06/2006
1	Triglycerides (Triacylglycerol)IBA 09/2004
1	ResistinIBA 02/2004
1	tungstateIBA 11/2002
1	Streptozocin (Streptozotocin)FDA Link 11/2002
1	Niacinamide (Nicotinamide)FDA LinkGeneric 11/2002

Therapy/Procedure

4	Therapeutics 01/2018 - 09/2008
2	Glycemic Control 01/2014 - 12/2012